CD4 and neoplasm: In pre-clinical studies the general outcome of combining anti-angiogenic agents with immunotherapy shows increased tumor regression and overall survival, often associated with relief of immunosuppression, evidenced by reduced presence of tumor resident MDSC and Treg cells, which often coincided with increased infiltration of CD4 and CD8 T cells (9, 31–34, 187, 188, 221).